CoChat

Blood‐based detection of RAS mutations to guide anti‐EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue‐based RAS testing

Open access
Schmiegel, Wolff, Scott, Rodney J., Dooley, Susan, Lewis, Wendy, Meldrum, Cliff J., Pockney, Peter, Draganic, Brian, Smith, Steve, Hewitt, Chelsee, Philimore, Hazel, Lucas, Amanda, Shi, Elva, Namdarian, Kateh, Chan, Timmy, Acosta, Danilo, Ping‐Chang, Su, Tannapfel, Andrea, Reinacher‐Schick, Anke, Uhl, Waldemar, Teschendorf, Christian, Wolters, Heiner, Stern, Josef, Viebahn, Richard, Friess, Helmut, Janssen, Klaus‐Peter, Nitsche, Ulrich, Slotta‐Huspenina, Julia, Pohl, Michael, Vangala, Deepak, Baraniskin, Alexander, Dockhorn‐Dworniczak, Barbara, Hegewisch‐Becker, Susanne, Ronga, Philippe, Edelstein, Daniel L., Jones, Frederick S., Hahn, Stephan, Fox, Stephen B. · 2017 · Molecular Oncology
Cited by 152

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

An accurate blood‐based RAS mutation assay to determine eligibility of metastatic colorectal cancer (mCRC) patients for anti‐EGFR therapy would benefit clinical practice by better informing decisions to administer treatment independent of tissue availability. The objective of this study was to determine the level of concordance between plasma and tissue RAS mutation status in patients with mCRC to gauge whether blood‐based RAS mutation testing is a viable alternative to standard‐of‐care RAS tumor testing. RAS testing was performed on plasma samples from newly diagnosed metastatic patients, or from recurrent mCRC patients using the highly sensitive digital PCR technology, BEAM ing (beads, emulsions, amplification, and magnetics), and compared with DNA sequencing data of respective FFPE (formalin‐fixed paraffin‐embedded) tumor samples. Discordant tissue RAS results were re‐examined by BEAM ing, if possible. The prevalence of RAS mutations detected in plasma (51%) vs. tumor (53%) was similar, in accord with the known prevalence of RAS mutations observed in mCRC patient populations. The positive agreement between plasma and tumor RAS results was 90.4% (47/52), the negative agreement was 93.5% (43/46), and the overall agreement (concordance) was 91.8% (90/98). The high concordance of plasma and tissue results demonstrates that blood‐based RAS mutation testing is a viable alternative to tissue‐based RAS testing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/1878-0261.12023

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 152

Metadata

Authors
Schmiegel, W., Scott, R. J., Dooley, S., Lewis, W., Meldrum, C. J., Pockney, P., Draganic, B., Smith, S., Hewitt, C., Philimore, H., Lucas, A., Shi, E., Namdarian, K., Chan, T., Acosta, D., Ping‐Chang, S., Tannapfel, A., Reinacher‐Schick, A., Uhl, W., Teschendorf, C., Wolters, H., Stern, J., Viebahn, R., Friess, H., Janssen, K., Nitsche, U., Slotta‐Huspenina, J., Pohl, M., Vangala, D., Baraniskin, A., Dockhorn‐Dworniczak, B., Hegewisch‐Becker, S., Ronga, P., Edelstein, D. L., Jones, F. S., Hahn, S., & Fox, S. B.
Venue
Molecular Oncology
Publisher
Wiley
Published
2017-01-20
Volume
11
Issue
2
Pages
208-219
ISSN
  • 1574-7891 (ISSN-L)
  • 1878-0261
OpenAlex
W2574977410
Cited by
152
References
25
FWCI
7.86
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blood‐based detection of RAS mutations to guide anti‐EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue‐based RAS testing. https://app.cochat.ai/papers/10.1002/1878-0261.12023
The paper
Schmiegel, W., Scott, R. J., Dooley, S., Lewis, W., Meldrum, C. J., Pockney, P., Draganic, B., Smith, S., Hewitt, C., Philimore, H., Lucas, A., Shi, E., Namdarian, K., Chan, T., Acosta, D., Ping‐Chang, S., Tannapfel, A., Reinacher‐Schick, A., Uhl, W., . . . Fox, S. B. (2017). Blood‐based detection of RAS mutations to guide anti‐EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue‐based RAS testing. Molecular Oncology. https://doi.org/10.1002/1878-0261.12023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.